
Core Viewpoint - The annual report summary of Lushin Venture Capital Group Co., Ltd. highlights the company's financial performance, profit distribution plan, and the current state of the investment and abrasive industries in 2024. Company Overview - Lushin Venture Capital's main business includes venture capital and abrasive manufacturing, with venture capital being the primary source of profit [7][8]. Financial Performance - For the fiscal year 2024, the net profit attributable to the parent company is CNY 161.93 million, with a total distributable profit of CNY 2.68 billion after accounting for retained earnings and cash dividends [3]. - The proposed profit distribution plan suggests a cash dividend of CNY 0.7 per 10 shares, totaling CNY 52.11 million [3]. Industry Analysis Abrasive Industry - The abrasive industry is experiencing a downward trend in revenue and profit due to changes in domestic and international market demand, with imports totaling USD 720 million and exports at USD 3.58 billion in 2024 [4]. Venture Capital Industry - The venture capital sector is undergoing significant regulatory changes aimed at enhancing market quality and risk prevention, as outlined in the "New National Nine Articles" and subsequent policies [5][6]. - In 2024, the Chinese private equity market raised CNY 1.44 trillion, a decrease of 20.8% year-on-year, with the number of new funds dropping by 43% [7]. - Investment activity also declined, with 8,408 cases reported, a 10.4% decrease, while the total disclosed investment amount fell by 10.3% to CNY 603.65 billion [7]. Business Operations Abrasive Business - The abrasive business operates primarily in the non-metallic mineral products industry, focusing on production and sales, serving clients in military, automotive, aerospace, and precision machining sectors [8]. Venture Capital Business - The venture capital business has established a rigorous investment management and risk control system, focusing on sectors such as information technology, energy conservation, new materials, and biomedicine [9][10].